Home › Non-Hodgkin Lymphoma › Alabama
Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma sa Alabama
7 pag-aaral para sa Non-Hodgkin Lymphoma ang naghahanap ng mga kalahok sa mga site sa Alabama.
Mga Lungsod sa Alabama
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of Alabama At Birmingham Hospital, Birmingham
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119DALY II USA/ MB-CART2019.1 for DLBCL
- University of Alabama at Birmingham, Birmingham
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Alabama at Birmingham, Birmingham
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
- University of Alabama, Birmingham
Nagre-recruitPhase 2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Hun 13, 2025 · NCT05253495Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.